British biotech company T-Therapeutics raises a £48M Series A round to discover and develop novel T cell receptor (TCR) therapeutics for cancer indications

T-Therapeutics is developing ‘optimal’ TCR based therapeutics using its proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. Here are details of T-Therapeutics latest funding round :

🚀 Launch

2022

🏭 Industry

Biotechnology

🧠Management

Allan Bradley (CEO)

💸 Funding & Investors

INVESTMENT (Novembre 2023)£48 million (Series A)
INVESTORS (Novembre 2023)led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital (CIC) with participation from Sanofi Ventures and the University of Cambridge Venture Fund.

🎯 Funding purpose

Discover and develop novel T cell receptor (TCR) therapeutics for cancer indications as well as inflammatory disorders.

🌐 Country HQ

UK (Cambridge)

Leave a Reply

Your email address will not be published.